Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
20.11.2017 16:00:00

Mylan to Present at Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference

HERTFORDSHIRE, England and PITTSBURGH, Nov. 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its president, Rajiv Malik, will present at the Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference in Boston, Mass., on Thursday, Nov. 30, 2017, at 3:50 p.m. ET. The discussion will focus on Mylan's robust pipeline and current dynamics in the generics industry.

Mylan (PRNewsfoto/Mylan N.V.)

Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's website at investor.mylan.com. An archived version also will be available following the live presentation and can be accessed at the same location for a limited time.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/mylan-to-present-at-evercore-isi-inaugural-biopharma-catalystdeep-dive-conference-300559359.html

SOURCE Mylan N.V.

Nachrichten zu Mylan N.V.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Mylan N.V.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!